Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
Status:
Recruiting
Trial end date:
2024-10-30
Target enrollment:
Participant gender:
Summary
This is a modular, phase I/ phase 1 b, open-label, multicentre study of ceralasertib
administered orally in combination with cytotoxic chemotherapy regimens and/or novel
anti-cancer agents, to patients with advanced malignancies. The study design allows an
investigation of optimal combination dose of ceralasertib with other anti-cancer treatments,
with intensive safety monitoring to ensure the safety of the patients. The initial
combination to be investigated is ceralasertib with carboplatin. The second combination to be
investigated is ceralasertib with Olaparib. The third combination to be investigated is
ceralasertib with durvalumab